Polymerase News and Research

RSS

Henry Ford study identifies 23 microRNAs for laryngeal cancer

A Henry Ford Hospital study has identified 23 microRNAs for laryngeal cancer, a discovery that could yield new insight into what causes certain cells to grow and become cancerous tumors in the voice box.

14 Sep 2011

Combining cell biology and molecular genetics for single-cell research

Fluidigm Corporation has announced a collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), to co-host a public seminar series on the isolation and analysis of single cells. Entitled 'A Powerful Technique for Single-Cell Analysis', the public seminar series will showcase cell isolation using the BD FACSAria™ III Cell Sorter and analysis using the Fluidigm BioMark™ HD System.

13 Sep 2011

Gilead to amend design of ongoing clinical trials against chronic hepatitis C

Gilead Sciences, Inc. today announced that, in consultation with the U.S. Food and Drug Administration (FDA), the company will amend the design of ongoing clinical trials to discontinue dosing of GS 9190 in hepatitis C-infected patients who are receiving that compound in combination with pegylated interferon and ribavirin, and another direct-acting antiviral agent.

5 Sep 2011

Medivir reports net sales of SEK 444.6 m for 1 January - 30 June 2011

Medivir: Interim period (January 2011 - June 2011). Net sales were SEK 444.6 (35.7) m.

31 Aug 2011

FDA grants fast track designation for Pharmasset's PSI-938 to treat chronic HCV infection

Pharmasset, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for PSI-938 for the treatment of chronic hepatitis C virus (HCV) infection.

24 Aug 2011

Noninvasive prenatal DNA test can detect fetus at risk for sex-linked disorders

As a noninvasive method of determining the sex of a fetus, tests using cell-free fetal DNA obtained from the mother's blood after 7 weeks gestation performed well, while urine-based tests appear to be unreliable, according to a review and analysis of previous studies, reported in the August 10 issue of JAMA.

10 Aug 2011

Inhibitex second quarter net loss decreases to $5.3 million

Inhibitex, Inc. today announced its financial results for the second quarter ended June 30, 2011 and provided an update on several recent clinical and corporate developments.

8 Aug 2011

BD Biosciences, Fluidigm to co-host public seminars on isolation and analysis of single cells

Fluidigm Corporation announced today a collaboration with BD Biosciences, a segment of BD, to co-host a public seminar series on the isolation and analysis of single cells. Entitled A Powerful Technique for Single-Cell Analysis, the public seminar series will showcase cell isolation using the BD FACSAria III Cell Sorter and analysis using the Fluidigm BioMark HD System.

From BD (Becton, Dickinson and Company) 5 Aug 2011

BioCryst second quarter total revenues decrease to $3.7 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

Gold nanoparticles for rapid, accurate diagnosis of flu

Arriving at a rapid and accurate diagnosis is critical during flu outbreaks, but until now, physicians and public health officials have had to choose between a highly accurate yet time-consuming test or a rapid but error-prone test.

4 Aug 2011

NanoString introduces new assay for leukemia fusion gene analysis

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of a comprehensive multiplexed assay for the simple and cost-effective analysis of fusion genes linked to leukemia.

From NanoString Technologies 29 Jul 2011

Genetic ID introduces new 96-well extraction kit for isolation of pure DNA

Genetic ID, the global leader in GMO identification, introduces its new FAST ID 96-Well Extraction Kit for isolation of exceptionally pure DNA from a variety of agricultural and food products.

21 Jul 2011

Altogen Labs introduces pyrosequencing services for hospitals, research institutions

Altogen Labs, a biology contract research organization and provider of pre-clinical research services, announced its launch of a pyrosequencing service today.

20 Jul 2011

Mayo Clinic licenses M. tuberculosis complex speciation test from QIAGEN

Mayo Clinic has licensed patent rights from QIAGEN to enable Mayo Medical Laboratories to offer an M. tuberculosis complex speciation test. The test expands Mayo Medical Laboratories' current offering for tuberculosis testing, which already includes M. tuberculosis complex culture, molecular identification and drug susceptibility testing.

From QIAGEN Manchester Limited 19 Jul 2011

BioMarin commences BMN 673 Phase 1 trial in hematological malignancies

BioMarin Pharmaceutical Inc. today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.

15 Jul 2011

Arabidopsis thaliana helps scientists to solve puzzles in human health

A tiny plant called Arabidopsis thaliana just helped scientists unearth new clues about the daily cycles of many organisms, including humans. This is the latest in a long line of research, much of it supported by the National Institutes of Health, that uses plants to solve puzzles in human health.

14 Jul 2011

Cumulus cells can provide information about genetic and chromosomal status of eggs

At present, when a woman undergoes preimplantation genetic screening (PGS) in a fertility clinic, doctors are trying to select an egg or an embryo that is healthy and doesn't have a chromosome abnormality such as an extra copy of chromosome 21, which causes Down's syndrome. In order to establish this, they either have to biopsy a part of the egg called the polar body or remove a cell from the embryo for screening. Both procedures are expensive, invasive and can damage the egg or embryo.

6 Jul 2011

TCGA examines ovarian serous adenocarcinoma tumors from 500 patients

An analysis of genomic changes in ovarian cancer has provided the most comprehensive and integrated view of cancer genes for any cancer type to date. Ovarian serous adenocarcinoma tumors from 500 patients were examined by The Cancer Genome Atlas (TCGA) Research Network and analyses are reported in the June 30, 2011, issue of Nature.

30 Jun 2011

New 3D herpes infection model brings hope

Herpes infections on the lips, in the eyes or on the nose are painful, long-lasting and unpleasant. A new 3D herpes infection model brings hope: active ingredients and new treatments can be reliably tested with this model. Animal tests could soon be a thing of the past.

27 Jun 2011

Pharmasset receives U.S. patent titled 'Nucleoside Phosphoramidate Prodrugs'

Pharmasset, Inc. announces that the United States Patent and Trademark Office has issued U.S. patent 7,964,580 titled "Nucleoside Phosphoramidate Prodrugs".

22 Jun 2011